Market Analysis by covering: Euro US Dollar, US Dollar Japanese Yen, Nasdaq 100, FTSE 100. Read 's Market Analysis on Investing.com ...

By Libby George and Karin Strohecker LONDON, Dec 19 (Reuters) - Emerging markets defied tariffs, trade wars and global turmoil to notch up stellar double-digit returns in 2025, and investors are hopeful of a repeat performance next year. Years of painful fiscal choices and central bankers who made all the right calls have left once-risky ​countries looking solid in the face of political and economic clouds in the United States and Europe, and rising geopolitical fragmentation. "There are a lot of tailw ...

Core Points - Danish Aerospace Company A/S is changing its Certified Advisor due to the termination of collaboration with Baker Tilly Corporate Finance [1][2] - HC Andersen Capital has been appointed as the new Certified Advisor, effective January 1, 2026 [2] Company Overview - Danish Aerospace Company A/S operates in advanced medical instrumentation and engineering fields, primarily focused on space applications [3][4] - The company specializes in developing, integrating, and applying medical technologies for space, with products benefiting both space research and terrestrial applications [3][4] - Danish Aerospace Company has developed various equipment for spaceflight, including respiratory equipment and bicycle ergometers for astronauts [4][5] - The company's quality system is certified to BS EN ISO 9001:2015 and BS EN 9100:2018, which are recognized standards in the industry [5]

California regulators reduced the profit that utilities are allowed to make on infrastructure investments in an effort to rein in soaring electricity bills.Related: Massive Wildfire Liabilities Push Utilities to Use AI to Stop Blazes The move Thursday by the California Public Utilities Commission underscores its oft-conflicting policy goals: while the state is keen for power providers to fortify a grid that’s sparked catastrophic wildfires, doing so costs billions of dollars. Those expenses are typically pa ...

Nike Inc. (NYSE:NKE) reported an EPS of $0.53, beating the estimated $0.37 and marking a significant earnings surprise of 43.24%.The company's revenue for the quarter was $12.43 billion, exceeding expectations and showcasing a slight increase from the previous year.Despite a decrease in profit margins, Nike's financial metrics indicate strong liquidity and a balanced financing approach, with a P/E ratio of 38.43 and a current ratio of 2.19.Nike Inc. (NYSE:NKE) is a global leader in the design, development, ...

Core Insights - IBA has acquired ORA, a leader in radiochemistry, enhancing its position in the nuclear medicine sector [1][2] - The acquisition aims to integrate IBA's cyclotron technology with ORA's advanced solutions, providing competitive offerings for hospitals and radiopharmacy networks [3] - This move aligns with IBA's strategic initiatives in nuclear medicine, including partnerships for isotope production and innovation in patient care [4] Financial Aspects - The acquisition is valued between €15-20 million on a cash-free, debt-free basis and is expected to be immediately accretive to IBA's revenue and EBITDA [5] - The transaction will be financed through IBA's own funds and existing credit facilities, with no material impact on IBA's 2025 financial guidance [5] Company Profiles - IBA is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people [7] - ORA Group is recognized for its automated PET radiopharmaceutical synthesizers, contributing to the production of sterile injectable PET drug products [8]

Core Insights - Chagee Holdings Limited has released its inaugural Sustainability Report for 2024, marking a significant milestone in the fresh tea beverage industry's sustainability journey [1] - The report highlights the company's integration of sustainability across its entire value chain, emphasizing cultural heritage, industrial collaboration, and ecological protection [2] Group 1: Company Overview - Chagee is a leading premium tea drinks brand founded in 2017, transforming traditional tea culture into a modern lifestyle experience [7] - The company aims to connect the world through tea, achieving progress in market expansion, product innovation, social responsibility, and global presence [3] Group 2: Sustainability Themes - **Culture**: Chagee partners with traditional artisan communities and cultural heritage programs to preserve techniques and promote Chinese tea culture globally [4] - **Connection**: The company has donated over RMB 4 million to build 37 multifunctional playgrounds benefiting over 5,000 rural children and operates silent stores for hearing-impaired individuals [4] - **Health**: Chagee ensures customer safety and health throughout the product life cycle and became the first fresh tea beverage brand to implement Shanghai CDC's "Nutritional Grading" standards [6] - **Ecology**: The company has built fresh milk supply networks reducing transportation carbon emissions by 70% and promotes sustainable packaging and new energy vehicle usage [5] Group 3: Social Responsibility and Employee Care - Chagee engages in disaster relief and supports underprivileged groups while ensuring rigorous health standards [7] - The "Night Clean Plan" covers approximately 1,000 stores, focusing on employee safety and work-life balance [6]

Company Overview - Clariant is a focused specialty chemical company with a purpose of "Greater chemistry – between people and planet" [2] - The company aims to create sustainable solutions across various industries by connecting customer focus, innovation, and people [2] - As of December 31, 2024, Clariant employed 10,465 staff and reported sales of CHF 4.152 billion for its continuing businesses [2] Business Structure - Since January 2023, Clariant operates through three Business Units: Care Chemicals, Catalysts, and Adsorbents & Additives [2] - The company is headquartered in Switzerland [2]

Core Points - Clariant has divested its business in Venezuela, selling Clariant Venezuela S.A. for approximately USD 1.8 million (CHF 1.4 million) to CMV Química, C.A. as part of its footprint optimization strategy [1] - In 2024, Clariant's operations in Venezuela generated sales of around CHF 3 million and employed about 60 people [1] - Following the divestment, a cumulative translation adjustment (CTA) of approximately CHF 236 million will be recycled through the income statement, impacting reported net profit and earnings per share for 2025, but will not affect cash flow or profitability guidance [2] Company Overview - Clariant is a sustainability-focused specialty chemical company, with a total staff of 10,465 and recorded sales of CHF 4.152 billion in the fiscal year for its continuing businesses as of December 31, 2024 [6] - The company operates through three business units: Care Chemicals, Catalysts, and Adsorbents & Additives [6]

Core Insights - Ipsen announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP) compared to placebo, leading to the closure of the study [1] - The investigational product, fidrisertib, was generally well tolerated with no safety concerns reported during the trial [1] Summary by Sections FALKON Trial Results - The FALKON trial was the largest Phase II trial for FOP, enrolling 113 patients globally over a period of more than 5 years [2][5] - The primary endpoint was the annualized change from baseline in HO volume, which was not achieved [5] Patient Impact and Community Response - The results are seen as disappointing for the FOP community, but the data is expected to contribute to ongoing research and understanding of the disease [2] - Ipsen expressed gratitude to the patients, caregivers, and the FOP community for their commitment to the trial [2] About FOP - FOP is a genetic condition caused by pathogenic variants of the ALK2 kinase, leading to irreversible bone formation in soft tissues [3] - The average age of diagnosis is 5 years, with a median life expectancy of 56 years due to complications from bone formation [3] - FOP has an estimated prevalence of 1.36 per million individuals, with approximately 900 diagnosed cases worldwide [3] About Fidrisertib - Fidrisertib is an oral small molecule inhibitor targeting pathogenic variants of the ALK2 kinase, designed to address both flare-up and non-flare-up based HO formation [4] - It is administered orally, either sprinkled on food or dissolved in water, without dose changes during flare-ups [4] Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience [6] - The company has nearly 100 years of development experience and operates in over 40 countries, bringing medicines to more than 100 countries [6]